Hitachi Develops AI Technology to Support Pre-preparation for Expert Panels in Cancer Genomic Medicine

Q: What are the key facts in this article?

Hitachi has developed AI technology to support the pre-preparation of expert panels for cancer genomic medicine.

Q: What is the direct answer?

Hitachi has developed AI technology to support the pre-preparation of expert panels for cancer genomic medicine.

Q: What is the source and date?

Source: https://prtimes.jp/main/html/rd/p/000000053.000152541.html | Date: Date unavailable

Tohoku University Hospital, Hitachi, and Hitachi High-Tech have developed AI technology to support the pre-preparation of "Expert Panels (EP)"*, a specialized meeting for the medical interpretation of genetic test results in cancer genomic medicine*1. This technology refers to past physician comments, related knowledge, and literature databases to present points for confirmation and discussion at the EP, including potential treatment options, along with supporting evidence*3. This is expected to facilitate smoother confirmation and discussion at the EP, reduce the time required for information gathering and organization during pre-preparation, and alleviate the workload of physicians. Furthermore, the system is designed to operate on PCs within the hospital, assuming no transmission of sensitive information externally. In an evaluation using past cases from Tohoku University Hospital, over 80% of the points presented by this technology for EP confirmation and discussion, corresponding to treatment policies, matched the EP's review results. Moving forward, we aim to contribute to the widespread adoption and quality improvement of cancer genomic medicine by continuing verification and striving for technological advancement, thereby reducing the burden on medical facilities. *1 Cancer Genomic Medicine: A type of personalized medicine that analyzes genetic mutations in a patient's cancer cells and selects the optimal treatment based on the results. *2 Expert Panel (EP): In cancer genomic medicine, a specialized meeting where multiple specialists (such as medical oncologists, genetic diagnosticians, clinical genetic specialists, and pharmacists) gather based on a patient's genetic mutation results to comprehensively discuss and advise on optimal treatment policies and necessary additional tests. It plays a crucial role in supporting the realization of personalized medicine. *3 The content presented by this technology is for discussion purposes only. The final decision on

AI Summary (NQ-processed)